摘要
Objective: To evaluate the addition of vindesine to acyclophosphamide-epirubicin-cisp (CAP) regimenfor treating the patients with locally advanced non-smallcell lung cancer (NSCLC). Methods: From May 1994to August 1998, 59 previously untreated patients withstage IIIa and IIIb non-small cell lung cancer wereenrolled into this trial. Patients characteristics were thefollowing: the median age was 52 years; the medianperformance status was 1; there were 19 stage IIIa and40 stage IIIb; there were 47 adenocarcinoma, 10squamous cell carcinoma and 2 large cell carcinoma. AIIpatients were treated with vindesine (2 mg/m2, on day 1and day 8), cyclophosphamide (0.6/m2, on day 1),epirubicin (40 mg/m2, on day 1) and cisplatin (60 mg/m2,on day 1) every 3 or 4 weeks. Results: Four achieved acomplete response (6.8%), 29 achieved a partialresponse (49.2%), 15 had stable disease, and 10 hadprogressive disease. A clinical improvement was in 45 of59 patients (76.3%). The most frequent major toxiceffects were myelosuppression, nausea and vomiting.Conclusion: The vindesine with CAP regimen was activecombination chemotherapy in patients with locallyadvanced NSCLC accompanied by the limited sideeffects.
Objective: To evaluate the addition of vindesine to acyclophosphamide-epirubicin-cisp (CAP) regimenfor treating the patients with locally advanced non-smallcell lung cancer (NSCLC). Methods: From May 1994to August 1998, 59 previously untreated patients withstage IIIa and IIIb non-small cell lung cancer wereenrolled into this trial. Patients characteristics were thefollowing: the median age was 52 years; the medianperformance status was 1; there were 19 stage IIIa and40 stage IIIb; there were 47 adenocarcinoma, 10squamous cell carcinoma and 2 large cell carcinoma. AIIpatients were treated with vindesine (2 mg/m2, on day 1and day 8), cyclophosphamide (0.6/m2, on day 1),epirubicin (40 mg/m2, on day 1) and cisplatin (60 mg/m2,on day 1) every 3 or 4 weeks. Results: Four achieved acomplete response (6.8%), 29 achieved a partialresponse (49.2%), 15 had stable disease, and 10 hadprogressive disease. A clinical improvement was in 45 of59 patients (76.3%). The most frequent major toxiceffects were myelosuppression, nausea and vomiting.Conclusion: The vindesine with CAP regimen was activecombination chemotherapy in patients with locallyadvanced NSCLC accompanied by the limited sideeffects.
